Business Context and Reporting Period
Company: Aldeyra Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2014
Reporting Period: The filing reports on events occurring on November 7, 2014, and references the quarter ended September 30, 2014.
Key Financial Metrics and Agreements
This filing details a new credit facility rather than standard quarterly financial results. Key metrics include:
- Total Loan Availability: Up to $5,000,000 in term loans from Square 1 Bank.
- Tranche A: $2,000,000 expected to be available on or about November 10, 2014.
- Tranche B: $3,000,000 contingent on satisfactory Phase II data evaluation for SLS or Uveitis indications, a verbal request from Domain Associates, and a clinical progress report.
- Interest Rate: Variable annual rate equal to the greater of 2.0% plus prime or 5.25% per annum.
- Repayment Terms: Interest-only payments prior to November 2015; monthly principal and interest installments over 36 months thereafter.
- Prepayment: Allowed without penalty or premium before November 2018.
- Facility Fee: $2,500 paid upon entry into the agreement.
- Warrant Issuance: Upon funding of Tranche B, the Company will issue a warrant for 3% of the principal amount divided by the lesser of the average closing bid/ask or average closing price over the preceding 10 business days. The warrant expires in 10 years.
- Covenants: Following the initial drawdown of Tranche B, the Company must maintain a cash balance of at least $3,000,000 with Square 1.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (revenue, profit, or cash flow) for the quarter ended September 30, 2014, as this 8-K focuses on the new financing agreement. The material change is the amendment of the Loan and Security Agreement dated April 12, 2012, to increase available capital and adjust terms.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Proceeds are designated to refinance outstanding loans, fund clinical trial expenses, and support general working capital.
- The Company issued a press release on November 10, 2014, regarding results of operations for the quarter ended September 30, 2014, which is incorporated by reference but not detailed in this text.
- Forward-Looking Statements: The filing contains forward-looking statements regarding product candidates, clinical trial success, regulatory approval, and market size. Actual results may differ materially due to risks including trial timing, regulatory hurdles, and financing needs.
- Collateral: The credit facility is secured by substantially all of the Company's personal property and intellectual property.
- Financial Covenants: Future financial covenants must be mutually agreed upon within 10 days of the Tranche B drawdown.
Important Facts for Investor Verification
- Verify the specific terms of the "Second Amendment" to the Loan and Security Agreement (Exhibit 10.2) for detailed covenants and default provisions.
- Confirm the status of the Phase II data for SLS or Uveitis indications, as this is a condition precedent for the $3,000,000 Tranche B funding.
- Review the press release dated November 10, 2014 (Exhibit 99.1) for actual revenue, cash flow, and burn rate figures for the quarter ended September 30, 2014, which are not explicitly stated in this 8-K text.
- Monitor the Company's ability to maintain the required $3,000,000 cash balance with Square 1 following the Tranche B drawdown.
- Assess the dilution impact of the warrant issuance upon the funding of Tranche B.